Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Justin Brown

Nurse Practitioner, Family Fort Wayne, IN Nurse Practitioner

NPI 1134358005 CMS profile 10756355

7900 W Jefferson Blvd, Fort Wayne, IN 46804

Open in the dashboard

General payments

$141,902

934 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Brown of Fort Wayne, IN is reported in the CMS Open Payments database as having received $141,902 across 934 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $70,008 228
2024 General $19,731 157
2023 General $4,097 163
2022 General $28,791 216
2021 General $19,275 170

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Brown
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Justin Brown were reported at $70,008. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Justin Brown Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $19,275 $124 $35–$379 $132
2022 $28,791 $141 $44–$430 $149
2023 $4,097 $154 $49–$476 $160
2024 $19,731 $165 $51–$504 $164
2025 $70,008 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Corcept Therapeutics $86,413 205 payments
  2. Novo Nordisk Inc $40,971 162 payments
  3. AstraZeneca Pharmaceuticals LP $5,447 53 payments
  4. Lilly USA, LLC $1,089 66 payments
  5. Abbott Laboratories $769 57 payments
  6. Tandem Diabetes Care, Inc. $735 40 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $573 47 payments
  8. Recordati_Rare_Diseases_Inc. $540 33 payments
  9. Medtronic, Inc. $510 33 payments
  10. Dexcom, Inc. $424 20 payments
  11. Other $4,432 218 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $100,843 76 payments
  2. Food and Beverage $17,517 780 payments
  3. Travel and Lodging $16,214 70 payments
  4. Honoraria $7,261 4 payments
  5. Education $67 4 payments
Products named General payments · program years 2021–2025
  1. Korlym $86,413 205 payments
  2. RYBELSUS $23,651 115 payments
  3. Ozempic $14,834 97 payments
  4. FARXIGA $5,387 52 payments
  5. MOUNJARO $659 34 payments
  6. t:slim X2 Insulin Pump with Control-IQ $597 33 payments
  7. ISTURISA $505 32 payments
  8. INPEN SMART INSULIN DELIVERY SYSTEM $467 30 payments
  9. AFREZZA $407 18 payments
  10. JARDIANCE $359 29 payments
  11. Other $8,314 483 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

4,127

Median for Nurse Practitioner: 389

Drug cost

$2,642,720

Median for Nurse Practitioner: $21,885

Branded share of claims

60.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 303 $488,340
Korlym Mifepristone Brand 21 $474,965
Mounjaro Tirzepatide Brand 201 $262,620
Xultophy 100-3.6 Insulin Degludec/Liraglutide Brand 122 $235,747
Jardiance Empagliflozin Brand 110 $125,582
Tresiba Flextouch U-200 Insulin Degludec Brand 82 $118,908
Farxiga Dapagliflozin Propanediol Brand 72 $79,752
Humalog Kwikpen U-200 Insulin Lispro Brand 20 $68,024
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 37 $66,025
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 42 $57,821

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$77,991

Medicare's payments for the services billed

Medicare patients

389

Average age 72

Services billed

1,907

212 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Ischemic heart disease 56%
Chronic kidney disease 49%
Arthritis 49%
Heart failure 43%
Atrial fibrillation 35%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
$17,682 21 —
JARDIANCE
$231 110 —
Ozempic
$124 303 —
MOUNJARO
$117 201 —
STRENSIQ
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

934 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record